Sun Pharmaceutical Industries Limited announced that new long-term data for LEQSELVI (deuruxolitinib) demonstrated sustained efficacy and safety in adults with severe alopecia areata. The findings were presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026, highlighting durable hair regrowth over a two-year period.

The featured oral presentation reported results from an open-label extension study evaluating treatment up to two years. The safety profile remained generally consistent with previous clinical experience. Most treatment-emergent adverse events were mild or moderate, and discontinuations due to adverse events were uncommon. No deaths, thrombosis, or major adverse cardiovascular events were reported among patients receiving the FDA-approved dose of 8 mg twice-daily.

Long-term efficacy outcomes

Analyses presented in a poster indicated durable scalp hair regrowth through Week 108 in patients receiving LEQSELVI in the European open-label extension. Among baseline responders who maintained their response at Week 52 and continued in the study, 93.9% maintained that response at Week 108. Additionally, 76.6% of baseline nonresponders achieved a response by Week 52. Of those who achieved this response and continued, 96.8% maintained it at Week 108.

Clinical significance and portfolio context

Arash Mostaghimi, Vice Chair of Clinical Trials and Innovation at Brigham and Women’s Hospital, noted that severe alopecia areata is a chronic autoimmune disease where long-term treatment considerations are critical. He stated that the data reinforce the growing body of evidence supporting LEQSELVI as a long-term treatment option. Ahmad Naim, Senior Vice President and North America Chief Medical Officer at Sun Pharma, emphasized that the data expand understanding beyond initial treatment response to include long-term tolerability and durability of benefit.

The company presented seven presentations on LEQSELVI at the congress, which was part of 22 total presentations from Sun Pharma across its dermatology and immunology portfolio. Pooled post hoc analyses of THRIVE-AA1 and THRIVE-AA2 trials showed consistent efficacy across clinically relevant subgroups, including patients with eyebrow, eyelash, or nail involvement.

What the numbers show

The data reveals a strong conversion rate from non-response to response within the first year, with 76.6% of initial nonresponders achieving clinical success by Week 52. This high conversion rate suggests that a significant portion of the patient population may derive benefit even if they do not respond immediately. Furthermore, the high maintenance rates (93.9% and 96.8%) among responders indicate that once clinical benefit is established, it is highly likely to persist over the two-year observation period, addressing a key concern in chronic autoimmune management.

Sun Pharmaceutical Industries Limited released its ESG Overview for FY26, detailing significant progress in environmental sustainability and corporate governance. The report highlights a 15.86% reduction in absolute Scope 1 and 2 carbon emissions compared to the 2020 baseline, alongside a 48.64% decrease in specific intensity.

The company’s reporting boundary now covers 44 manufacturing locations and R&D centers, representing approximately 97% of revenues for EHS indicators. This expansion from the previous 79% coverage ensures a more comprehensive assessment of operational impacts across its global footprint.

Environmental performance metrics

Sun Pharma achieved a 16.05% reduction in absolute water consumption and a 48.72% decrease in specific intensity against the 2020 baseline. Renewable energy sources accounted for 43% of total energy consumption during the fiscal year.

The company maintained zero environmental non-compliance issues and reported zero fines or penalties related to biodiversity violations. Hazardous waste co-processing reached 37.93%, while 73.24% of total waste was diverted from landfill through recycling, reuse, or co-processing.

Social and governance highlights

In terms of social impact, Sun Pharma recorded an INR 2,068 million CSR spend, touching nearly 2.23 million lives in India. Female representation across the global workforce stood at 17.97%, with women holding 13.44% of top management positions. The company reported zero cases of corruption, bribery, or customer privacy data breaches.

Governance structures remained robust, with an average board meeting attendance of 95.24% and 50% independent directors on the board. The CEO-to-employee pay ratio was calculated at 119.17, reflecting compensation structures aligned with global best practices.

What the numbers show

A notable divergence appears between absolute emission reductions and specific intensity improvements. While absolute emissions fell by 15.86%, specific intensity dropped by 48.64%. This disparity suggests that revenue growth outpaced the rate of absolute emission reduction, indicating that while operational efficiency improved significantly, total output volume increased substantially. The expansion of the reporting boundary to include more sites likely contributed to the rise in absolute figures, yet the sharp decline in intensity underscores effective decarbonization per unit of revenue.